Stay updated on Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial page.

Latest updates to the Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial page
- Check5 days agoChange DetectedAdded the iRECIST guidelines citation (Lancet Oncology, 2017) to the Publications section and removed the associated erratum notice (Lancet Oncology, 2019).SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedUpdated iRECIST guideline reference to the 3.4.3 revision (including the erratum) and removed the older 3.4.2 citation.SummaryDifference0.1%

- Check55 days agoChange DetectedDifference0.1%

- Check62 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed. This appears to be a minor software version update with no visible changes to the study details.SummaryDifference0.1%

- Check77 days agoChange DetectedAdded a Show glossary option and updated the Study Record Dates to display 'Last Update Submitted that Met QC Criteria'. The page footer now includes 'No FEAR Act Data' and a new 'Revision: v3.4.0' note.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial page.